Skip to Content

'
Sushovan Guha, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Gastroenterology, Hepatology and Nutrition, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Bio Statement

Sushovan Guha obtained his MD degree with distinction from University of Madras, India and moved to the US for a Molecular Pathology Fellowship at the University of Illinois, Chicago. Dr. Guha then graduated with MPhil in Microbiology and Immunology from Columbia University, New York. Next, he completed his internship and residency in internal medicine at the Albert Einstein College of Medicine in Bronx, New York. Dr. Guha then joined the prestigious Specialty Training and Advanced Research (STAR) Fellowship in Gastroenterology and Hepatology at the David Geffen School of Medicine at UCLA, Los Angeles where he received his PhD also from the Molecular Biology Institute.

Dr. Guha is a board certified clinical gastroenterologist and physician-scientist at The University of Texas MD Anderson Cancer Center (MDACC). Some of his recent awards include MDACC Physician Scientist Program, Research Scholar Award from American Gastroenterological Association (AGA), AGA Research Excellence in GI and Liver Award, APA R. L. Hirshberg Award in Pancreatic Cancer Research (Basic Science), and MDACC Cyrus Scholar Award for Basic Science.

Research Interests

The research focus in my Laboratory of signal transduction in GI cancers consists of unraveling signal transduction pathways in pancreatic cancer (PaCa). The following are some of the highlights of our research activities in the past years:

  • G protein-coupled receptor (GPCR) mediated mitogenic and angiogenic pathways in pancreatic cancer (PaCa)
  • Biological roles of Neutrophil gelatinase associated lipocalin (NGAL) in PaCa

My major collaborative research at MDACC includes:

  • Biological and therapeutic significance of increased tissue transglutaminase (TG2) expression in pancreatic cancer (PaCa)
  • Curcumin and other bioactive botanical agents in pancreatic and colorectal cancers
  • Curcumin as a therapeutic agent in clinical trials at MDACC, USA and Kyoto, Japan

Clinical Interests

  • Pancreatic Cancer
  • Gastrointestinal Diseases
  • Chemoprevention of Cancer

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 1466
Houston, TX 77030
Room Number: FCT13.6002
Phone: 713-745-7566
Fax: 713-745-9295
Email: sguha@mdanderson.org

Education & Training

Degree-Granting Education

2005 Molecular Biology Institute, UCLA, Los Angeles, CA, PHD, Molecular Biology
1995 Columbia University, New York, NY, MA, Microbiology and Immunology
1995 Columbia University, New York, NY, MPhil, Microbiology and Immunology
1988 University of Madras, Madras, India, MD, Medicine

Postgraduate Training

9/1999-6/2005 Specialty Training and Advanced Research (STAR) Fellowship/Graduate Student, Molecular Biology Institute, UCLA, Los Angeles, CA
7/1998-6/2003 Specialty Training and Advanced Research (STAR) Fellow in Gastroenterology, David Geffen School of Medicine at UCLA, Los Angeles, CA
7/1995-6/1998 Internship and Residency in Internal Medicine, Albert Einstein College of Medicine Affiliated Hospitals, New York, NY
6/1992-6/1995 Graduate Student, Department of Microbiology and Immunology, Columbia University, New York, NY
5/1989-5/1992 Fellowship in Pathology, University of Illinois School of Medicine, Chicago, IL
2/1987-2/1988 Internship, Jawaharlal Institute of Post Graduate Medical Education & Research Hospital, Pondicherry, India

Board Certifications

2008 American Board of Internal Medicine, Gastroenterology
1998 American Board of Internal Medicine

Experience/Service

Other Appointments/Responsibilities

Member, Barrett's Esophagus and Esophageal Cancer SPORE group, Houston, TX, 2007-present
Member, Pancreatic Cancer Working Group, Houston, TX, 2006-present
Member, Botanical Research Center Group at The UT MD Anderson Cancer Center, Houston, TX, 2006-present

Institutional Committee Activities

Clinical Member, India Steering Committee-Global Academic programs at UT MDACC, 9/2008-present
Member, Institute of Personalized Cancer Therapy (IPCT)-GI Cancer, 9/2008-present
Member, Division of Internal Medicine Research Committee, 7/2006-present
Member, UT GI Fellows Training Committee, 7/2005-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers M, Rashid A, and Maru DM. Anti-phosphorylated Histone H3 expression in Barrett's Esophagus, Low-Grade Dysplasia, High-Grade Dysplasia, and Adenocarcinoma. Modern Pathology. In Press.
2. Sandur S, Deorukhkar A, Pandey M, Pabon AM, Shentu S, Guha S, Aggarwal B, and Krishnan S. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kB acitivity. International Journal of Radiation Oncology Biology Physics. In Press.
3. Kunnumakkara A, Diagaradjane P, Anand P, Kumar H, Deorukhkar A, Gelovani J, Guha S, Krishnan S, and Aggarwal B. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of Cyclin D1, COX2, MMP9, VEGF, and CXCR4 expression in an orthotopic mouse model. International Journal of Cancer. In Press.
4. Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung M-C, Ajani JA, and Huang P. Diffrent redox states in malignant and non-malignant esophageal epithelial cells and differential cytotoxic responses to bile acids and honokiol. Antioxidants and Redox Signaling. In Press.
5. Matsuo Y, Sawai H, Ochi N, Yasuda A, Sakamoto M, Takahashi H, Funahashi H, Takeyama H, and Guha S. MG132 blocks pancreatic cancer angiogenesis through inhibition of NF-kB activity. Digestive Diseases and Sciences. In Press.
6. Sung B, Kunnumakkara A, Sethi G, Anand P, Guha S, and Aggarwal B. Curcumin circumvents chemoresistance and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Molecular Cancer Therapeutics 8(4):959-970, 2009.
7. Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z, Burdick MD, Yang Z, Strieter RM, Hoffman RM, and Guha S. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. International Journal of Cancer 125(5):1027-1037, 2009.
8. Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, Takeyama H, Tong Z, and Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasiveness and angiogenesis in pancreatic cancer. International Journal of Cancer 124(4):853-861, 2009.
9. Maru D, Luthra R, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Correa A, Swisher S, Ajani J, Hofstetter W, and Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 115(7):1576-1585, 2009.
10. Matsuo Y, Campbell P, Brekken R, Sung B, Ouellette M, Fleming J, Aggarwal B, Der C, and Guha S. K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through MAP kinase signaling pathways. Molecular Cancer Research 7(6):799-808, 2009.
11. Harikumar K, Kunnumakkara A, Ahn K, Anand P, Krishnan S, Guha S, and Aggarwal B. Modification of the cysteine residues in IκBα kinase and NF-κB (p65) by xanthohumol leads to suppression of NF-κB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood 113(9):2003-2013, 2009.
12. Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, Takeyama H, and Guha S. Role of pancreatic cancer cells secreted IL-1a in promoting angiogenesis and its therapeutic implications. Journal of Surgical Research 153(2):274-281, 2009.
13. Yen C, Izzo J, Lee D, Guha S, Wei Y, Wu T, Chen C, Kuo H, Chou C, Hsu J, Sun H, DeMars C, Buttar N, Wang K, Huang P, Ajani J, and Hung M. Bile acid exposure causes upregulation of TSC1/mTOR signal pathway in Barrett's esophagus-associated esophageal adenocarcinoma. Cancer Research 68(8):2632-2640, 2008.
14. Kunnumakkara A, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal B, and Krishnan S. Curcumin sensitizes human colorectal cancer xenograft in nude mice to gamma-radiation by targeting NF-kB regulated gene products. Clinical Cancer Research 14(7):2128-2136, 2008.
15. Tong Z, Kunnumakkara A, Wang H, Matsuo Y, Diagaradjane P, Harikumar K, Ramachandran V, Sung B, Chakraborty A, Bresalier R, Logsdon C, Aggarwal B, Krishnan S, and Guha S. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Research 68(15):6100-6108, 2008.
16. Verma A, Guha S, Koul D, Gao Y, Wang H, Abbruzzesse J, and Mehta K. Regulation of tumor suppressor protein PTEN by tissue transglutaminase: mechanistic linkage and prognostic significance in pancreatic cancer. Clinical Cancer Research 14(7):1997-2005, 2008.
17. Guha S, Verma A, Diagaradjane P, Kunnumakkara A, Sanguino A, Lopez-Berestein G, Sood, A, Aggarwal B, Krishnan S, Gelovani J, and Mehta K. Therapeutic significance of elevated tisuue transglutaminase expression in pancreatic cancer. Clinical Cancer Research 14(8):2476-2483, 2008.
18. Sung B, Jhurani S, Ahn K, Matsuo Y, Yi T, Guha S, Liu M, and Aggarwal B. Zerumbone downregulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. Cancer Research 68(21):8938-8944, 2008.
19. Bhutani M, Pathak A, Nair A, Kunnumakkara A, Guha S, Sethi G, and Aggarwal B. Capsaicin is a novel blocker of constitutive and IL-6 inducible STAT-3 activation: its role in suppression of proliferation and of chemoresistance through the regulation of cell survival gene products in human multiple myeloma cells. Clinical Cancer Research 13(10):3024-3032, 2007.
20. Song S, Guha S, Liu K, Buttar N, and Bresalier R. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signaling pathways in Barrett’s esophagus and esophageal carcinoma. Gut 56(11):1512-1521, 2007.
21. Guha S, Kunnumakkara A, Krishnan S, Diagaradjane P, Gelovani J, and Aggarwal B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Research 67(8):3853-3861, 2007.
22. Chakrabarty A and Guha S. G-CSF/G-CSFR biological axis promotes survival and growth of bladder cancer cells. Urology 69(6):1210-1215, 2007.
23. Pathak A, Bhutani M, Nair A, Ahn K, Chakraborty A, Guha S, Sethi G, and Aggarwal B. Ursolic acid inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells by inhibiting constitutive and IL-6 inducible STAT-3 activation pathway. Molecular Cancer Research 5(9):943-955, 2007.
24. Chakraborty A, White S, and Guha S. Granulocyte colony-stimulating receptor promotes beta1-integrin-mediated adhesion and invasion of bladder cancer cells. Urology 68(1):208-13, 2006. PMID: 16844458.
25. Krishnan S, Rana V, Janjan N, Abbruzzese J, Gould M, Das P, Delclos M, Palla S, Guha S, Varadhachary G, Evans D, Wolff R, and Crane C. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107(11):2589-96, 2006. PMID: 17083124.
26. Guha S, Eibl G, Kisfalvi K, Fan R, Burdick M, Reber H, Hines OJ, Strieter R, and Rozengurt E. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Research 65(7):2738-45, 2005. PMID: 15805273.
27. Kisfalvi K, Guha S, and Rozengurt E. Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. J Cell Physiol 202(3):880-90, 2005. PMID: 15389644.
28. Okada Y, Eibl G, Guha S, Duffy J, Reber H, and Hines OJ. Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clinical and Experimental Metastasis 21(4):285-292, 2004.
29. Guha S, Lunn J, Santiskulvong C, and Rozengurt E. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Research 63(10):2379-87, 2003. PMID: 12750255.
30. Guha S, Rey O, and Rozengurt E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Research 62(6):1632-40, 2002. PMID: 11912133.
31. Dulai G, Guha S, Kahn K, Gornbein J, and Weinstein W. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: A systematic review. Gastroenterology 122(1):26-33, 2002.
32. Ryder N, Guha S, Hines O, Reber H, and Rozengurt E. G protein-coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation. J Cell Physiol 186(1):53-64, 2001. PMID: 11147814.
33. Lawrence C, Tuma R, Guha S, Michael H, Lowy FD, and Shuter J. Multiple antibiotic changes during the first 72 hours of hospitalization. American Journal of Medical Science 322(2):61-67, 2001.
34. Strober B, Dunaief J, Guha S, and Goff S. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Molecular and Cell Biology 16(4):1576-1583, 1996.
35. Dunaief J, Strober B, Guha S, Khavari P, Alin K, Luban J, Begemann M, Crabtree G, and Goff SP. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79(1):119-130, 1994.

Invited Articles
1. Bhutani MS, Verma D, Guha S, Lee JH, Richards-Kortum RR, and Fleming JB. Is Endoscopic Ultrasound "Sound" for Pancreatic Cancer Screening? Journal of Clinical Gastroenterology. In Press.
2. Kunnumakkara AB, Guha S, and Aggarwal BB. Curcumin and colorectal cancer: add spice to your life. Current Colorectal Cancer Reports 5:5-14, 2009.
3. Guha S, Kaunitz J. Gastroduodenal mucosal defense - an integrated protective response. Current Opinion in Gastroenterology 18:650-657, 2002.
4. Rozengurt E, Guha S, Sinnett-Smith J. Gastrointestinal peptide signaling in health and disease. Eur J Surg Suppl 587:23-38, 2002. PMID: 16144198.

Abstracts
1. Raimondo M, Gill K, Wallace M, Woodward T, Matsuo Y, Guha S. Can CXC-chemokines and lipocalin 2 in pancreatic juice (PJ) distinguish chronic pancreatitis (CP) from pancreatic cancer (PC)? APA Annual Meeting, Chicago, IL, 11/2008.
2. Thrower E, Yuan J, Kelly M, Jones C, Pandol S, Guha S. Protein Kinase D: a novel regulator of zymogen activation and amylase secretion in acute pancreatitis. APA Annual Meeting, Chicago, IL, 11/2008.
3. Matsuo Y, Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasion and angiogenesis of pancreatic cancer. Digestive Disease Week, San Diego, CA, 5/2008.
4. Guha S, Verma A, Mehta K. Tissue transglutaminase downregulation potentiates gemcitabine efficacy and blocks pancreatic cancer growth in vivo. Digestive Disease Week, San Diego, CA, 5/2008.
5. Guha S, Chakraborty A, Kunnumakkara A, Slawomir S, Fokt I, Abbruzzese J, Aggarwal B, Madden T, Priebe W. A novel JAK2-STAT3 inhibitor blocks mitogenesis and angiogenesis in pancreatic cancer. AACR, San Diego, CA, 4/2008.
6. Tong Z, Matsuo Y, Kunnumakkara A, Wang H, Chakraborty A, Aggarwal B, Krishnan S, Guha S. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. AACR San Diego, CA, 4/2008.
7. Mehta K, Verma A, Guha S, Fok J, Lopez-Berestein G, Sood A. Therapeutic significance of elevated tissue transglutaminase (TG2) expression in pancreatic cancer. AACR, San Diego, CA, 4/2008.
8. Chakraborty A, Guha S, Helgason T, Szymanski S, Fokt I, Kazerooni R, Madden T, and Priebe W. A novel Jak2/STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cancer cells. AACR Annual meeting, Los Angeles, CA, 2007.
9. Guha S, Matsuo Y, Hoffman R, Burdick M, Strieter R. Blockade of CXC-chemokine receptor 2 inhibits angiogenesis in an orthotopic model of pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
10. Kunnumakkara A, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal B, Guha S. Curcumin potentiates anti-tumor activity of gemcitabine in an orthotopic model of pancreatic cancer: role in inhibition of proliferation, angiogenesis, and NF-kB regulated gene products. AGA DDW Annual Meeting, Los Angeles, CA, 2007.
11. Kunnumakkara A, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal B, Guha S. Curcumin potentiates anti-tumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of NF-kB regulated gene products. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
12. Guha S, Bresalier R, Hoffman R, Burdick M, Strieter R. CXC-chemokines/CXCR2 mediate a novel pathway of angiogenesis in pancreatic cancer. AACR Annual Meeting, Los Angeles, CA, 2007.
13. Matsuo Y, Ochi N, Takeyama H, Sawai H, Okada Y, Manabe T, Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasion and angiogenesis of pancreatic cancer. American Pancreatic Association (APA) Annual Meeting, Chicago, Illinois, 2007.
14. Matsuo Y, Ochi N, Takeyama H, Sawai H, Okada Y, Manabe T, Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasion and angiogenesis of pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
15. Matsuo Y, Ochi N, Takeyama H, Sawai H, Okada Y, Manabe T, Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasion and angiogenesis of pancreatic cancer. Int'l Society of Gastrointestinal Oncology (ISGIO) Annual Meeting, Philadelphia, Pennsylvania, 2007.
16. Guha S, Verma A, Kunnumakkara A, Diagaradjane P, Krishnan S, Gelovani J, Aggarwal B, Lopez-Bernstein G, Mehta K. Inhibition of tissue transglutaminase expression potentiates gemcitabine effects in reducing tumor growth and metastasis in an orthotopic model of pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
17. Tong Z, Matsuo Y, Wang H, Maitra A, Chakraborty A, Krishnan S, Guha S. Neutrophil gelatinase associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. International Society of Gastrointestinal Oncology (ISGIO) Annual Meeting, Philadelphia, Pennsylvania, 2007.
18. Tong Z, Wang H, Guha S. Neutrophil gelatinase associated lipocalin: a novel suppressor of invasion in pancreatic cancer. AGA DDW Annual Meeting, Los Angeles, CA, 2007.
19. Tong Z, Wang H, Chakraborty A, Guha S. Neutrophil gelatinase associated lipocalin: a novel suppressor of invasion in pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
20. Guha S, Verma A, Sood A, Lopez-Berestein G, Mehta K. Transglutaminase-2 (TG2) as therapeutic target for pancreatic cancer. 4th International Tumor Progression and Therapeutic Resistance Meeting, Philadelphia, PA, 2007.
21. Guha S, Chakraborty A, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Madden T, Priebe W. WP1066, a potent inhibitor of JAK2/STAT3 pathway inhibits pancreatic cancer growth both in vitro and in vivo. AACR Annual meeting, Los Angeles, CA, 2007.
22. Guha S, Chakraborty A, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Madden T, Priebe W. WP1066, a potent inhibitor of JAK2/STAT3 pathway inhibits pancreatic cancer growth both in vitro and in vivo. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.

Book Chapters
1. Spinn MP, and Guha S. Small Bowel Tumors. In: Textbook of Clinical Gastroenterology and Hepatology, 2nd edition. Wiley-Blackwell. In Press.
2. Guha S. Other GI tumors. In: Gastroenterology and Hepatology: The Modern Clinician’s Guide, 1st edition. Weinstein WM, Hawkey CJ, and Bosch J, 2005.

Grant & Contract Support

Title: Role of CXC-chemokines/CXCR2 Biological Axis in Pancreatic Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2010 - 3/31/2015
 
Title: Biological Role of Lipocalin 2 in Pancreatic Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 12/1/2009 - 11/30/2011
 
Title: Interplay of oxidative DNA damage repair and inflammation in pancreatic carcinoma
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 10/5/2008 - 9/30/2010
 
Title: Biological role of neutrophil gelatinase associated lipocalin in pancreatic cancer
Funding Source: UT MDACC IRG
Role: Principal Investigator
Duration: 10/1/2008 - 9/30/2009
 
Title: Targeting the microenvironment of NSCLC with kinase inhibitors
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Dr. J. Minna and Dr. J. Roth
Duration: 7/1/2008 - 6/30/2013
 
Title: Biological and therapeutic significance of TG2 in pancreatic cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Dr. K. Mehta
Duration: 7/1/2008 - 6/30/2010
 
Title: Biological role of lipocalin 2 in pancreatic cancer
Funding Source: NIH/NIDDK
Role: Principal Investigator-MDACC
Principal Investigator: Dr. M. Estes
Duration: 3/1/2008 - 2/28/2009
 
Title: TG2 in growth, development, and progression of pancreatic cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Dr. K. Mehta
Duration: 12/1/2007 - 11/30/2012
 
Title: Role of CXCR2 ligands/CXCR2 biological axis in pancreatic cancer
Funding Source: Mayo Clinic IRG
Role: Co-Investigator
Duration: 9/1/2007 - 8/31/2009
 
Title: G protein-coupled receptors: novel targets in pancreatic cancer
Funding Source: UT MDACC PSP
Role: Principal Investigator
Duration: 9/1/2005 - 8/31/2010
 
Title: G Protein coupled receptors: novel targets in pancreatic cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Dr. J. Mendelsohn
Duration: 7/1/2005 - 6/30/2006
 
Title: Synergy between Neurotensin and EGF in promoting mitogenic signaling and cellular proliferation of human pancreatic cancer
Funding Source: AGA Research Scholar Award
Role: Principal Investigator
Duration: 7/1/2004 - 6/30/2007
 
Title: Neurotensin mediated signaling pathways in pancreatic cancer
Funding Source: NIH/NIDDK
Role: Co-Investigator
Duration: 2/1/2002 - 11/30/2004

Last updated: 9/15/2009